Clinic
Banner Gateway Medical Center
Banner Gateway Medical Center was paid $55.88M by Medicaid between Jan 2018 and Dec 2024, across 423 billing codes. Its largest line is 99285, emergency room visit (most serious) — 15% of everything it billed.
33Billing provider infoBANNER GATEWAY MEDICAL CENTER
GILBERT, AZ 85234
GILBERT, AZ 85234
33aNPI1699884858assigned 08/30/2006
33bProvider typeInfusion Therapy Clinic/Center
28Total paid$55.88M
24GClaims1,544,018
24DCodes billed423
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Infusion Therapy Clinic/Center providers in Arizona
Rank by total paid#2 of 7
Median peer was paid$275K
This provider vs. median203×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 190,492 | $6.32M | |
| 2019 | 187,736 | $6.99M | |
| 2020 | 174,591 | $6.47M | |
| 2021 | 255,427 | $8.63M | |
| 2022 | 256,359 | $9.00M | |
| 2023 | 260,308 | $9.95M | |
| 2024incomplete | 219,105 | $8.51M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 15% | 23,389 | 21,307 | $8.35M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 14% | 37,362 | 34,368 | $8.00M |
| J9271 | Injection, pembrolizumab, 1 mg | 11% | 1,032 | 734 | $6.38M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 9.5% | 10,836 | 10,207 | $5.30M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 7.9% | 23,887 | 22,648 | $4.43M |
| 80053 | Comprehensive metabolic panel | 3.5% | 95,232 | 62,669 | $1.93M |
| 88185 | 3.2% | 3,918 | 2,029 | $1.77M | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2.7% | 4,301 | 4,029 | $1.51M |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | 2.4% | 322 | 180 | $1.32M |
| J9299 | Injection, nivolumab, 1 mg | 2.1% | 324 | 187 | $1.19M |
| 78815 | Positron emission tomography (PET) for limited area imaging | 2.0% | 1,691 | 1,562 | $1.09M |
| 81455 | 1.7% | 257 | 227 | $927K |
411 more codes
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.6% | 2,800 | $873K |
| 36430 | 1.5% | 4,285 | $845K | |
| J2505 | Injection, pegfilgrastim, 6 mg | 1.4% | 274 | $763K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.3% | 16,341 | $731K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.3% | 6,545 | $709K |
| Q5111 | Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg | 1.1% | 305 | $591K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.0% | 5,906 | $570K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 42,161 | $556K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,845 | $481K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 518 | $386K |
| 77334 | <1% | 458 | $375K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,408 | $328K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 3,326 | $296K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 1,044 | $290K |
| 88341 | <1% | 3,510 | $289K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,766 | $263K |
| 47562 | <1% | 70 | $256K | |
| J9355 | Injection, trastuzumab, excludes biosimilar, 10 mg | <1% | 237 | $243K |
| 43235 | <1% | 662 | $233K | |
| J0897 | Injection, denosumab, 1 mg | <1% | 340 | $202K |
| 70491 | <1% | 1,268 | $197K | |
| 77386 | <1% | 1,189 | $197K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 694 | $174K |
| 71250 | <1% | 1,568 | $165K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 13,166 | $160K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 497 | $143K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 1,601 | $143K |
| G0378 | Hospital observation service, per hour | <1% | 10,388 | $132K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 4,291 | $127K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 1,699 | $121K |
| C9399 | Unclassified drugs or biologicals | <1% | 971 | $116K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 1,108 | $115K |
| J9035 | Injection, bevacizumab, 10 mg | <1% | 49 | $115K |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 2,510 | $110K |
| C1769 | Guide wire | <1% | 1,644 | $95K |
| 88377 | <1% | 1,139 | $95K | |
| 36561 | <1% | 67 | $95K | |
| 87799 | <1% | 1,767 | $92K | |
| J9263 | Injection, oxaliplatin, 0.5 mg | <1% | 161 | $91K |
| 93971 | <1% | 1,914 | $89K | |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 3,849 | $82K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 5,635 | $67K |
| 81268 | <1% | 238 | $64K | |
| 0225U | <1% | 137 | $54K | |
| 93970 | <1% | 282 | $53K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 23,980 | $50K |
| 93975 | <1% | 2,167 | $47K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 3,508 | $44K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 8,737 | $44K |
| Q5107 | Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg | <1% | 111 | $43K |
| 96367 | <1% | 6,003 | $41K | |
| 76642 | <1% | 919 | $41K | |
| J2997 | Injection, alteplase recombinant, 1 mg | <1% | 628 | $39K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 5,449 | $39K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 164 | $37K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,216 | $37K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 17,010 | $35K |
| 88307 | <1% | 1,946 | $35K | |
| 77301 | <1% | 14 | $34K | |
| 77336 | <1% | 1,944 | $34K | |
| 77066 | Tomosynthesis, mammo | <1% | 545 | $33K |
| 96401 | <1% | 1,506 | $32K | |
| 76536 | <1% | 498 | $31K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 486 | $30K |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | <1% | 29 | $29K |
| 96411 | <1% | 1,664 | $29K | |
| 87497 | <1% | 2,903 | $28K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 33,143 | $27K |
| 74174 | <1% | 41 | $27K | |
| 96417 | <1% | 5,445 | $25K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 375 | $25K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 11,179 | $24K |
| 96402 | <1% | 1,287 | $24K | |
| 36591 | <1% | 17,832 | $23K | |
| 70496 | <1% | 45 | $21K | |
| J1439 | Injection, ferric carboxymaltose, 1 mg | <1% | 47 | $21K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 188 | $21K |
| 74183 | <1% | 99 | $20K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 2,080 | $20K |
| 82728 | <1% | 5,061 | $19K | |
| 74230 | <1% | 169 | $19K | |
| J9070 | Cyclophosphamide, 100 mg | <1% | 158 | $18K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 11,575 | $18K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 10,401 | $18K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 15 | $16K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 3,173 | $14K |
| 78306 | <1% | 200 | $13K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 2,015 | $11K |
| 96376 | <1% | 9,766 | $11K | |
| J3490 | Unclassified drugs | <1% | 44,934 | $11K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 16,376 | $10K |
| J9206 | Injection, irinotecan, 20 mg | <1% | 19 | $9K |
| 86850 | <1% | 6,280 | $9K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 98,849 | $8K |
| P9037 | Platelets, pheresis, leukocytes reduced, irradiated, each unit | <1% | 584 | $8K |
| 77065 | Tomosynthesis, mammo | <1% | 403 | $8K |
| J9201 | Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | <1% | 43 | $8K |
| J9202 | Goserelin acetate implant, per 3.6 mg | <1% | 15 | $7K |
| 80320 | <1% | 3,637 | $7K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 746 | $7K |
| 88374 | <1% | 500 | $7K | |
| 96415 | <1% | 5,064 | $6K | |
| 70486 | <1% | 104 | $6K | |
| 86923 | <1% | 2,274 | $6K | |
| 93976 | <1% | 1,249 | $6K | |
| 36592 | <1% | 10,841 | $6K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 4,142 | $6K |
| 86900 | <1% | 7,090 | $5K | |
| 94060 | <1% | 58 | $5K | |
| J1750 | Injection, iron dextran, 50 mg | <1% | 29 | $5K |
| 86635 | <1% | 1,535 | $5K | |
| 82784 | <1% | 6,001 | $5K | |
| 92611 | <1% | 168 | $4K | |
| 36593 | <1% | 442 | $4K | |
| 87631 | <1% | 2,501 | $4K | |
| 31579 | <1% | 13 | $4K | |
| 72131 | <1% | 12 | $3K | |
| A4648 | Tissue marker, implantable, any type, each | <1% | 50 | $3K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 7,107 | $3K |
| 81267 | <1% | 268 | $3K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 26 | $2K |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 35,399 | $2K |
| 72100 | <1% | 736 | $2K | |
| 73562 | <1% | 1,624 | $2K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 20,459 | $2K |
| 88342 | <1% | 4,125 | $2K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 11,059 | $2K |
| 77412 | <1% | 238 | $2K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 57 | $2K |
| 88344 | <1% | 84 | $2K | |
| J9190 | Injection, fluorouracil, 500 mg | <1% | 1,921 | $2K |
| 71045 | Radiologic examination, chest; single view | <1% | 11,690 | $2K |
| 10060 | <1% | 39 | $1K | |
| 81025 | <1% | 15,657 | $1K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 16,152 | $1K |
| 76775 | <1% | 279 | $1K | |
| 88237 | <1% | 1,411 | $1K | |
| 74018 | <1% | 1,720 | $1K | |
| 84153 | <1% | 551 | $1K | |
| 76830 | Ultrasound, transvaginal | <1% | 1,638 | $1K |
| 84702 | <1% | 3,914 | $1K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,099 | $1K |
| J8597 | Antiemetic drug, oral, not otherwise specified | <1% | 5,014 | $1K |
| 87040 | <1% | 7,561 | $976.08 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 38,924 | $896.72 |
| 83690 | <1% | 17,523 | $828.42 | |
| 77080 | <1% | 12 | $820.95 | |
| 87081 | <1% | 825 | $778.10 | |
| P9040 | Red blood cells, leukocytes reduced, irradiated, each unit | <1% | 1,670 | $760.50 |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 4,351 | $740.04 |
| 73130 | <1% | 688 | $739.79 | |
| 73030 | <1% | 980 | $707.16 | |
| 84484 | <1% | 13,345 | $685.34 | |
| 88361 | <1% | 22 | $649.64 | |
| 76801 | <1% | 1,864 | $634.58 | |
| 82378 | <1% | 2,385 | $631.70 | |
| 97165 | <1% | 190 | $586.33 | |
| 96409 | <1% | 460 | $581.28 | |
| 73610 | <1% | 1,057 | $561.30 | |
| 80061 | Lipid panel | <1% | 662 | $536.74 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 18,876 | $514.31 |
| 81001 | <1% | 23,054 | $499.65 | |
| 82947 | <1% | 18,478 | $495.00 | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 14 | $490.83 |
| 96523 | <1% | 69 | $483.28 | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 1,875 | $480.99 |
| 84112 | <1% | 905 | $455.06 | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 578 | $451.31 |
| 97161 | <1% | 776 | $427.09 | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 119 | $370.30 |
| 73630 | <1% | 1,279 | $367.69 | |
| 85379 | <1% | 2,547 | $363.43 | |
| 83605 | <1% | 8,825 | $351.83 | |
| J2704 | Injection, propofol, 10 mg | <1% | 14,681 | $348.04 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,770 | $338.39 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,159 | $322.89 |
| 99152 | <1% | 1,017 | $322.86 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,159 | $322.47 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,460 | $315.12 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 81 | $295.72 |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,367 | $278.12 |
| 83880 | <1% | 2,377 | $274.53 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 5,561 | $261.93 |
| 85055 | <1% | 12,666 | $260.40 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 22,191 | $257.68 |
| 88184 | <1% | 3,070 | $251.76 | |
| 84550 | <1% | 2,566 | $239.05 | |
| 84703 | <1% | 4,265 | $237.04 | |
| 86920 | <1% | 229 | $236.02 | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,192 | $231.38 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 1,382 | $211.80 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 13,211 | $192.60 |
| A9270 | Non-covered item or service | <1% | 28,209 | $191.14 |
| 84439 | <1% | 4,303 | $189.38 | |
| J7999 | Compounded drug, not otherwise classified | <1% | 1,031 | $184.42 |
| 81003 | <1% | 12,131 | $177.36 | |
| 83970 | <1% | 17 | $174.39 | |
| 85610 | <1% | 10,759 | $173.93 | |
| 82607 | <1% | 2,333 | $171.59 | |
| 85027 | <1% | 10,817 | $170.98 | |
| 82805 | <1% | 428 | $170.69 | |
| 83735 | <1% | 33,751 | $160.19 | |
| 85730 | <1% | 4,489 | $160.05 | |
| 87070 | <1% | 1,221 | $157.38 | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 718 | $156.66 |
| 86140 | <1% | 3,751 | $153.76 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 11,174 | $138.65 |
| 90715 | <1% | 1,135 | $136.16 | |
| 88264 | <1% | 1,339 | $136.13 | |
| 84403 | <1% | 538 | $134.78 | |
| 87088 | <1% | 8,418 | $133.50 | |
| 87075 | <1% | 89 | $133.19 | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 2,685 | $121.84 |
| 86901 | <1% | 7,732 | $119.52 | |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | <1% | 412 | $111.79 |
| 88313 | <1% | 3,045 | $110.64 | |
| 73502 | <1% | 155 | $103.15 | |
| 73110 | <1% | 215 | $100.95 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,118 | $97.53 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 3,670 | $94.06 |
| 77280 | <1% | 16 | $88.13 | |
| 82550 | <1% | 2,241 | $87.62 | |
| 87186 | <1% | 3,397 | $85.50 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 8,890 | $82.82 |
| 86803 | <1% | 159 | $81.61 | |
| 88368 | <1% | 302 | $77.64 | |
| 83615 | <1% | 21,115 | $75.05 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,255 | $74.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,365 | $67.94 |
| 87077 | <1% | 4,267 | $65.09 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 7,609 | $63.31 |
| 82565 | <1% | 831 | $62.99 | |
| 76870 | <1% | 27 | $59.78 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 5,433 | $45.40 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 4,112 | $44.90 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 3,325 | $43.29 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 2,788 | $41.98 |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 532 | $41.37 |
| 74022 | <1% | 213 | $39.42 | |
| 86800 | <1% | 218 | $36.56 | |
| 88112 | <1% | 37 | $33.72 | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 2,316 | $32.96 |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 302 | $30.93 |
| 85652 | <1% | 2,083 | $29.53 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 3,996 | $29.43 |
| 96368 | <1% | 3,048 | $28.95 | |
| 87210 | <1% | 368 | $26.92 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 12,430 | $26.18 |
| 87807 | <1% | 334 | $24.58 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 8,757 | $24.30 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 331 | $22.50 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 468 | $19.76 |
| 87340 | <1% | 227 | $18.24 | |
| 84100 | <1% | 20,092 | $16.39 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 309 | $15.16 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 173 | $15.00 |
| 85018 | <1% | 1,487 | $14.42 | |
| A9503 | Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries | <1% | 188 | $14.33 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 412 | $12.88 |
| 85014 | <1% | 1,225 | $12.76 | |
| 85046 | <1% | 906 | $11.02 | |
| 88304 | <1% | 1,275 | $10.27 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 96 | $9.13 |
| 85007 | <1% | 3,606 | $8.72 | |
| 88311 | <1% | 1,649 | $7.81 | |
| 85384 | <1% | 267 | $7.63 | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 1,350 | $6.83 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 693 | $5.68 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 2,152 | $5.39 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 456 | $4.70 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 2,046 | $4.34 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 601 | $3.68 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 4,418 | $2.70 |
| J1815 | Injection, insulin, per 5 units | <1% | 3,267 | $2.61 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 8,863 | $0.81 |
| S0028 | Injection, famotidine, 20 mg | <1% | 1,410 | $0.66 |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 750 | $0.00 |
| 84466 | 0% | 3,107 | $0.00 | |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 122 | $0.00 |
| 96416 | 0% | 1,648 | $0.00 | |
| 84155 | 0% | 546 | $0.00 | |
| J0640 | Injection, leucovorin calcium, per 50 mg | 0% | 1,381 | $0.00 |
| 84165 | 0% | 1,902 | $0.00 | |
| 86360 | 0% | 1,071 | $0.00 | |
| J3489 | Injection, zoledronic acid, 1 mg | 0% | 610 | $0.00 |
| 84156 | 0% | 1,311 | $0.00 | |
| 83540 | 0% | 3,120 | $0.00 | |
| 84145 | 0% | 91 | $0.00 | |
| 88367 | 0% | 165 | $0.00 | |
| 76376 | 0% | 523 | $0.00 | |
| 84460 | 0% | 743 | $0.00 | |
| 84520 | 0% | 298 | $0.00 | |
| 88173 | 0% | 292 | $0.00 | |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 769 | $0.00 |
| 86359 | 0% | 1,072 | $0.00 | |
| 97116 | 0% | 190 | $0.00 | |
| 82570 | 0% | 130 | $0.00 | |
| J0692 | Injection, cefepime hydrochloride, 500 mg | 0% | 91 | $0.00 |
| 86038 | 0% | 14 | $0.00 | |
| 84450 | 0% | 403 | $0.00 | |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | 0% | 96 | $0.00 |
| 82232 | 0% | 677 | $0.00 | |
| 93356 | 0% | 636 | $0.00 | |
| 88373 | 0% | 170 | $0.00 | |
| J0736 | Injection, clindamycin phosphate, 300 mg | 0% | 159 | $0.00 |
| 82652 | 0% | 85 | $0.00 | |
| Q9961 | High osmolar contrast material, 250-299 mg/ml iodine concentration, per ml | 0% | 149 | $0.00 |
| J3105 | Injection, terbutaline sulfate, up to 1 mg | 0% | 235 | $0.00 |
| 76937 | 0% | 304 | $0.00 | |
| Q0114 | Fern test | 0% | 70 | $0.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 72 | $0.00 |
| 94664 | 0% | 395 | $0.00 | |
| 81265 | 0% | 66 | $0.00 | |
| 97803 | 0% | 141 | $0.00 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 2,963 | $0.00 |
| 86334 | 0% | 630 | $0.00 | |
| J0694 | Injection, cefoxitin sodium, 1 gm | 0% | 291 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 164 | $0.00 |
| 82248 | 0% | 151 | $0.00 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 383 | $0.00 |
| 94729 | 0% | 59 | $0.00 | |
| 86644 | 0% | 56 | $0.00 | |
| 12011 | 0% | 30 | $0.00 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 746 | $0.00 |
| J1956 | Injection, levofloxacin, 250 mg | 0% | 72 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 150 | $0.00 |
| 82747 | 0% | 328 | $0.00 | |
| C1788 | Port, indwelling (implantable) | 0% | 40 | $0.00 |
| 85048 | 0% | 120 | $0.00 | |
| 82731 | 0% | 39 | $0.00 | |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | 0% | 114 | $0.00 |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 0% | 13 | $0.00 |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | 0% | 13 | $0.00 |
| 82010 | 0% | 67 | $0.00 | |
| J9060 | Injection, cisplatin, powder or solution, 10 mg | 0% | 25 | $0.00 |
| 94726 | 0% | 40 | $0.00 | |
| J7510 | Prednisolone oral, per 5 mg | 0% | 14 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 48 | $0.00 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 12 | $0.00 |
| 80195 | 0% | 52 | $0.00 | |
| 88302 | 0% | 18 | $0.00 | |
| 77338 | 0% | 14 | $0.00 | |
| 73080 | 0% | 14 | $0.00 | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 13 | $0.00 |
| 82310 | 0% | 19 | $0.00 | |
| 87102 | 0% | 15 | $0.00 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 1,636 | $0.00 |
| 84132 | 0% | 731 | $0.00 | |
| J0456 | Injection, azithromycin, 500 mg | 0% | 150 | $0.00 |
| J9045 | Injection, carboplatin, 50 mg | 0% | 1,102 | $0.00 |
| J9267 | Injection, paclitaxel, 1 mg | 0% | 546 | $0.00 |
| 86357 | 0% | 742 | $0.00 | |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 2,776 | $0.00 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 0% | 262 | $0.00 |
| 83521 | 0% | 883 | $0.00 | |
| 83883 | 0% | 2,283 | $0.00 | |
| 99153 | Mod sedat endo service >5yrs | 0% | 450 | $0.00 |
| J2469 | Injection, palonosetron hcl, 25 mcg | 0% | 2,376 | $0.00 |
| 77063 | Screening digital breast tomosynthesis, bilateral | 0% | 454 | $0.00 |
| 87147 | 0% | 31 | $0.00 | |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 3,777 | $0.00 |
| 80197 | 0% | 1,581 | $0.00 | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | 0% | 1,610 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 369 | $0.00 |
| 86320 | 0% | 523 | $0.00 | |
| 70498 | 0% | 45 | $0.00 | |
| 86355 | 0% | 743 | $0.00 | |
| 94760 | 0% | 746 | $0.00 | |
| 86300 | 0% | 1,089 | $0.00 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 189 | $0.00 |
| 88369 | 0% | 286 | $0.00 | |
| 77300 | 0% | 202 | $0.00 | |
| 80329 | 0% | 332 | $0.00 | |
| 87205 | 0% | 899 | $0.00 | |
| 74021 | 0% | 116 | $0.00 | |
| 87533 | 0% | 60 | $0.00 | |
| 84432 | 0% | 161 | $0.00 | |
| 86301 | 0% | 473 | $0.00 | |
| 82105 | 0% | 102 | $0.00 | |
| 82746 | 0% | 683 | $0.00 | |
| 86308 | 0% | 16 | $0.00 | |
| C1781 | Mesh (implantable) | 0% | 26 | $0.00 |
| 87449 | 0% | 30 | $0.00 | |
| 83010 | 0% | 17 | $0.00 | |
| 88172 | 0% | 13 | $0.00 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 321 | $0.00 |
| 87632 | 0% | 13 | $0.00 | |
| 72040 | 0% | 56 | $0.00 | |
| 96377 | 0% | 20 | $0.00 | |
| 82330 | 0% | 64 | $0.00 | |
| 77001 | 0% | 76 | $0.00 | |
| G0008 | Administration of influenza virus vaccine | 0% | 54 | $0.00 |
| J3360 | Injection, diazepam, up to 5 mg | 0% | 40 | $0.00 |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 0% | 127 | $0.00 |
| J3411 | Injection, thiamine hcl, 100 mg | 0% | 18 | $0.00 |
| 90686 | 0% | 60 | $0.00 | |
| C2617 | Stent, non-coronary, temporary, without delivery system | 0% | 56 | $0.00 |
| J1720 | Injection, hydrocortisone sodium succinate, up to 100 mg | 0% | 72 | $0.00 |
| 36415 | Collection of venous blood by venipuncture | 0% | 14 | $0.00 |
| J1920 | Injection, labetalol hydrochloride, 5 mg | 0% | 74 | $0.00 |
| 86704 | 0% | 19 | $0.00 | |
| 97802 | 0% | 21 | $0.00 | |
| 12001 | 0% | 58 | $0.00 | |
| 71101 | 0% | 14 | $0.00 | |
| 36620 | 0% | 23 | $0.00 | |
| 86592 | 0% | 26 | $0.00 | |
| 82945 | 0% | 18 | $0.00 | |
| 84157 | 0% | 18 | $0.00 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 0% | 20 | $0.00 |
| J0461 | Injection, atropine sulfate, 0.01 mg | 0% | 22 | $0.00 |
| 87206 | 0% | 22 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMCCOLLEM, DARREN (CEO)
Parent organizationBANNER HEALTH